Scientists from the University of Surrey worked closely with counterparts from the Institut Laue-Langevin (ILL) in France, a leading facility in neutron science and technology, and CERN to find out more about the radioactive decay of Terbium 152, a medically relevant isotope that could help create revolutionary targeted cancer diagnosis and therapies.